Abstract:
Described are glycosylated, partially glycosylated or unglycosylated polypeptides with the amino-acid sequence given in the sequence protocol and in which up to 10 amino acid groups can be replaced by other, naturally occurring, amino acids. The peptides are suitable for use in treating illnesses.
Abstract:
The present invention relates to the use of pyrimidine compounds of the following formula:wherein R1, R2, R3, A, B and Ar have the meanings indicated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.
Abstract:
PCT No. PCT/EP95/02781 Sec. 371 Date Jan. 14, 1997 Sec. 102(e) Date Jan. 14, 1997 PCT Filed Jul. 14, 1995 PCT Pub. No. WO96/02520 PCT Pub. Date Feb. 1, 1996The present invention relates to triazole compounds of the following formula: where R1, R2, A, B and Ar have the meanings stated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.
Abstract:
The present invention relates to the use of pyrimidine compounds of the following formula:wherein R1, R2, R3, A, B and Ar have the meanings indicated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.
Abstract:
The use is disclosed of pyrimidine compounds having the formula (I), in which R1, R2, R3, A, B and Ar have the meanings given in the description. These compounds have a high affinity for the dopamine D3 receptor and are therefore useful for treating diseases that respond to dopamine D3 ligands.
Abstract:
PCT No. PCT/EP92/02198 Sec. 371 Date Mar. 18, 1994 Sec. 102(e) Date Mar. 18, 1994 PCT Filed Sep. 23, 1992 PCT Pub. No. WO93/09231 PCT Pub. Date May 13, 1993A novel thrombin inhibitory protein from ticks with a molecular weight of about 26000 dalton and the partial amino acid sequences Val-Ala-Lys-Phe-Ala-X-Asn-Ser-Gly-Ser-Glu-Thr-Gly (SEQ ID NO: 8), His-Ala-Y-Phe-Glu (SEQ ID NO: 3), Arg-Val-Ser-Asp-Phe-Glu (SEQ ID NO: 4), Phe-Val-Tyr-Thr-Ile-Glu (SEQ ID NO: 6), where X and Y can be identical or different and each is a naturally occurring amino acid, is suitable for controlling diseases.
Abstract:
PCT No. PCT/EP95/01099 Sec. 371 Date Sep. 30, 1996 Sec. 102(e) Date Sep. 30, 1996 PCT Filed Mar. 23, 1995 PCT Pub. No. WO95/26716 PCT Pub. Date Oct. 12, 1995A method of inhibiting endothelin receptors by administering to a patient a compound of the formula I I
Abstract:
PCT No. PCT/EP92/02661 Sec. 371 Date May 18, 1994 Sec. 102(e) Date May 18, 1994 PCT Filed Nov. 19, 1992 PCT Pub. No. WO93/11239 PCT Pub. Date Oct. 6, 1993.Novel thrombin-inhibitory proteins from terrestrial leeches of the genus Haemadipsa with the amino-acid sequence Ile-Arg-Phe-Gly-Met-Gly-Lys-Val-Pro-Cys-Pro-Asp-Gly-Glu-Val-Gly-Tyr-Thr-Cys-Asp-Cys-Gly-Glu-Lys-Ile-Cys-Leu-Tyr-Gly-Gln-Ser-Cys-Asn-Asp-Gly-Gln-Cys-Ser-Gly-Asp-Pro-Lys-Pro-Ser-Ser-Glu-Phe-Glu-Glu-Phe-Glu-Ile-Asp-Glu-Glu-Glu-Lys, or an amino-acid sequence which is obtained by C-terminal truncation of this sequence by from one to twelve amino acids, are described. The proteins are suitable for controlling diseases. Also described are the nucleic acids coding for these proteins.
Abstract:
PCT No. PCT/EP95/01099 Sec. 371 Date Sep. 30, 1996 Sec. 102(e) Date Sep. 30, 1996 PCT Filed Mar. 23, 1995 PCT Pub. No. WO95/26716 PCT Pub. Date Oct. 12, 1995A method of inhibiting endothelin receptors by administering to a patient a compound of the formula I I